I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Multiple Myeloma

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Jun 16 / Roche and Genentech
Cevostomab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: initial results from the Phase I/II CAMMA 2 study
CAMMA 2 is an ongoing Phase I/II study of cevostomab in patients with relapsed/refractory multiple myeloma. Initial efficacy and safety results from Cohort A1 (patients who are triple-class refractory and have received a prior B-cell maturation antigen-targeted agent or chimeric antigen receptor T-cell therapy) are reported.

Sign up or login to unlock the full suite of MEDICALLY features

Apr 17 / Roche and Genentech
Health resource utilization (HRU) in patients with multiple myeloma (MM) and cytogenetic abnormalities in the relapsed/refractory (R/R) setting: results using the Flatiron electronic health record (EHR) claims linked dataset
A retrospective observational study of patients with multiple myeloma in the United States, using linked data obtained from the Flatiron Health database and Komodo’s Healthcare Map. Healthcare utilisation by lines of treatment (LOT) in patients who have received ≥3 LOT, and by t(11;14) positivity and number of high-risk genetic abnormalities, are described in this poster.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 11 / Roche and Genentech
Real-World Incidence, Characteristics and Management of Cytokine Release Syndrome Induced by Chimeric Antigen Receptor T-Cell Therapies Across Hematological Malignancies
A real-world data study, using data obtained from the Flatiron Health database, of cytokine release syndrome (CRS), induced by commercially available chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies, was conducted. The real-world incidence, severity and clinical management of CRS induced by CAR-T therapies are reported.

Ask a question or share feedback